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ABSTRACT
Thyroid hormones are major determinants of skeletal
muscle differentiation In vivo. Triiodo-L-thyronlne
treatment promotes terminal muscle differentiation and
results In increased MyoD gene transcription in
myogenic cell lines; furthermore myoD and fastmyosln
heavy chain gene expression are activated In rodent
slow twitch muscle fibers (Molecular Endocrinology 6:
1185-1194, 1992; Development 118: 1137-1147,
1993). We have Identified a T3 response element (TRE)
in the mouse MyoD promoter between nucleotide
positions -337 and -309 (5' CJ QAGGTCAG J AC A-
GGCfGGAGGAGTAGA 3'). This sequence conferred an
appropriate T3 response to an enhanceriess SV40
promoter. In vitro binding studies showed that the
thyroid hormone receptor a (TRa) formed a
heterodimeric complex, with either the retinoid X
receptor a or 7I isoforms (RXRa, RXRy), on the MyoD
TRE that was specifically competed by other well
characterised TREs and not by other response
elements. Analyses of this heterodimer with a battery
of steroid hormone response elements Indicated that
the complex was efficiently competed by a direct repeat
of the AGGTCA motif separated by 4 nucleotides as
predicted by the 3 - 4 - 5 rule. EMSA experiments
demonstrated that the nuclear factor(s) present In
muscle cells that bound to the myoD TRE were
constltutlvely expressed during myogenesis; this
complex was competed by the myosin heavy chain,
DR-4 and PAL-0 TREs in a sequence specific fashion.
Western blot analysis Indicated that TRa1 was
constitutively expressed during C2C12 differentiation.
Mutagenesis of the myoD TRE indicated that the
sequence of the direct repeats (AGGTCA) and the 4
nucleotide gap were necessary for efficient binding to
the TRa/RXRa heterodimeric complex. In conclusion
our data suggest that the TRE in the helix loop helix
gene, myoD, is a target for the direct heterodimeric
binding of TRa and RXRa/7. These results provide a
molecular mechanism/model for the effects of triiodo-
L-thyronine on In vitro myogenesis; the activation of
myoD gene expression in the slow twitch fibres and the
cascade of myogenic events regulated by thyroid
hormone.
INTRODUCTION
Thyroid hormone levels play a major role in regulating contractile
protein isoform expression in vivo during adult muscle
development as highlighted by myosin heavy chain isoform
switches and the subsequent effects on the velocity of contraction
(1). Thyroid hormones exert marked effects on cardiac and
skeletal muscle, and result in a substantial reorganization of the
myocyte which in turn, alters contractile protein performance
and ion transport. In skeletal muscle, hyper-thyroidism results
in an increase in type II fast fibers, whereas hypothyroidism
results in a decrease in muscle mass and a reduced number of
myofibres (1-6) . Thyroid hormone regulates the steady-state
levels of a many different contractile protein mRNAs (1,7,8 and
references therein). Triiodo-L-thyronine treatment has been
shown to activate or repress gene expression in a fiber type
specific manner in adult rodents (1). Furthermore, embryonic
and neonatal genes can be re-induced in adult muscle fibers by
hypothyroidism (1). In general, long term hyper- and
hypothyroidism precipitates in the precocious and retarded
expression, respectively, of the normal contactile protein isoform
profile that is modulated during embryonic, neonatal and adult
development. The molecular basis for these observations
(2-6,9,10) has not been elucidated.
MyoD and myogenin mRNAs preferentially accumulate in fast
and slow twitch muscle respectively (9). Recently, it has been
observed that triiodo-L-thyronine treatment of myogenic cell lines
and adult rodents, promotes terminal muscle differentiation,
results in increased MyoD gene transcription and the activation
of MyoD gene expression in soleus slow twitch fibers (11,12).
The MyoD protein belongs to a family of myogenic specific helix
loop helix (HLH) proteins [MyoD, Myogenin, Myf-5,
MRF-4/myf-6/herculin] that directs the fate of pluripotential
mesodermal embryonic cells and indirectly/directly activate
muscle specific genes involved in terminal differentiation and
contraction. The MyoD gene family is differentially expressed
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and temporally regulated during embryonic and adult mouse
development. These proteins contain a 68 amino acid conserved
basic/myc-like region that is necessary and sufficient for myogenic
conversion. The basic region and adjacent HLH motif mediates
DNA binding and dimerisation. The MyoD family forms
heterodimers with ubiquitously expressed members of the HLH
protein family, such as E12 and E47 (the alternatively spliced
products of the E2A gene). The MyoD-E2A heterodimers bind
to a consensus DNA binding sequence, the E-box motif, that
includes a CANNTG motif, present in most muscle specific
enhancers (reviewed in 13,14,15). The expression and function
of these hierarchical regulators is modulated by growth factors,
oncogene products, innervation and hormones (summarised and
discussed in ref. 16).
The effects of thyroid hormones are mediated by the
intracellular thyroid hormone receptors (TR), that are encoded
by two distinct genes, c-erhA a and c-erbA jS. The c-erbA. a gene
is alternatively spliced into a l and a2 (hormone and non-hormone
binding) isoforms respectively. Intriguingly, the c-erbA a locus
has also been demonstrated to contained an overlapping
transcription unit utilizing coding information on the opposite
strand (rev-erb) . The al and rev-erb isoforms seem to regulate
the function of c-erbA-al (17,18). TRs bind to response elements
containing tandem direct [and degenerate] repeats, of the AGGT-
CA Nx AGGTCA motif with spacings of 3 or 4 nucleotides and
activate gene transcription (19—24). TR requires accessory/
auxiliary factors for high affinity binding to their cognate
sequences (25—27). The retinoid X receptor (RXR) family is
one of these accessory proteins that is activated by 9-cis retinoic
acid (9-cis RA). The RXRs heterodimerize with TRs and function
to selectively target the high affinity binding of these receptors
to their cognate elements (20,23,24,28,29,30).
Although TRs and RXRs are abundantly expressed in cardiac
and skeletal muscle, the studies to date did not reveal whether
the ligand activated thyroid hormone and retinoid X receptors
directly activated MyoD transcription in myogenic cell lines and
slow twitch fibers. In this report we document the identification
of a thyroid hormone response element (TRE) in the mouse myoD
gene that directly interacts with a thyroid hormone/retinoid X
receptor heterodimer; and characterise the sequences and motifs
in this TRE that are necessary for an efficient DNA-receptor
interaction. These results indicate that T3 directly controls the
expression of myogenic specific helix loop helix proteins and
provide a mechanism for the changes in the contactile protein
isoform profile observed in adult rodents exposed to T3.
MATERIAL AND METHODS
Cell culture and transfection
Mouse myogenic C2C12 cells were grown in Dulbecco modified
Eagle medium (DMEM) supplemented with 20% fetal calf serum
(FCS) in 6% CO2 as described previously (43). This cell line
was induced to biochemically and morphologically differentiate
into multinucleate myotubes by mitogen withdrawal [DMEM
supplemented with 2% fetal calf serum in 6% CO2].
Differentiation was essentially complete within 72—96 hours with
respect to isoform switching in the actin multigene family (22).
However, these cells will spontaneously differentiate at a very
high confluence (100%) in the presence of mitogens. COS-1 cells
were grown in DMEM supplemented with 10% FCS in 6%
COj.
COS-1 cells were cultured for 24h in T3 and T4 deficient
medium containing 5 % charcoal stripped FCS in DMEM prior
to transfection. Each 60mm dish of COS-1 cells (60-70 %
confluence) was transiently transfected with 4 - 5 /tg of reporter
plasmid DNA expressing Luciferase, mixed with 0.01 -2/ig of
receptor expression vectors and pUC18 plasmid to a total of 10
/ig in each transfection experiment by the DOTAP (Boehringer
Mannheim) mediated procedure as described previously (7,8).
The DNA/DOTAP mixture was added to the cells in 6 mis of
fresh culture (T3 and T4 deficient) medium. After a period of
24 hours, fresh medium ±T3 / 9-cis RA (10~7 M) was added
to the cells. The cells were harvested for the assay of Luciferase
enzyme activity 24 h after the transfection period. Each
transfection experiment was performed at least three times in
order to overcome the variability inherent in transfections (7,8).
Luciferase assays
Cells from 60 mm cell culture dishes were washed twice in PBS
and harvested in 200 y\ 1X cell culture lysis reagent (25 mM
Tris-phosphate pH 7.8, 2mM DTT, 2mM 1,2-diaminocyclo-
hexane-N,N,N', N'-tetraacetic acid, 10% glycerol , 1% Triton
and 1 mg/ml BSA. 5-20 /il of the cell extract was mixed with
100 ^ 1 of reconstituted Luciferase assay reagent (20 mM Tricine,
pH 7.8, 1.07 mM [MgCO3]4Mg[OH]2-5H2O, 2.67 mM
MgSO4, 0.1 mM EDTA, 33.3 mM DTT, 0.27 mM coenzyme
A, 0.47 mM luciferin and 0.53 mM ATP). The reactions were
placed in a luminometer after 20-45 second incubation, followed
by 5x5 second measurements.
Hasmids
The plasmid pGL-2-promoter [an enhancerless SV40 promoter
linked to luciferase in a pUC19 backbone] was purchased from
Promega. The plasmid, pCMV-rTRa expressing the rodent c-
erbA a gene in the eucaryotic expression vector CMV 4,
containing the cytomegalovirus promoter and SV40 origin of
replication was described by Zilz et al., 1990 (31). The plasmids,
pSG 5-RXRa and y expressing the mouse RXRa and y gene
in the eucaryotic expression vector, pSG5 containing the early
SV40 promoter; /3-globin intron II for splicing and SV40 origin
of replication was described by Leid et al. 1992 (28). The
pGEX-1-cTRa plasmid was described by Muscat et al. 1993 (7).
We constructed pGEX3-mRXR7l by excising the mouse RXR7I
cDNA from the pSG 5 expression vector by Eco Rl digestion.
This cDNA was cloned in frame into EcoRl cleaved pGEX-3.
Sense and anti-sense orientation clones were identified by two
double digests Pst \ I Hind m and Pst \IXba 1. The pGEX-2T-
hRXRa was described in Manglesdorf et al., 1991 (20). The
sense and anti sense strands of the myoD TRE sequences with
gate ends were annealed, phosphorylated with T4 polynucleotide
kinase and self ligated with T4 DNA ligase. These products were
then cloned into the Bgl II site in the pGL-2-promoter vector
from Promega and initially screened for inserts by Hind IE /Sac
I digestion. Clones identified by restriction analyses were
sequenced by double stranded sequencing to determine the
orientation and number of copies cloned. The clone utilised in
these studies pMyoD-GL-p contained three copies of the MyoD
TRE (-339/-307) in the following orientation - - —
(-307/-339) with respect to the direction of luciferase
transcription.
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Expression and purification of receptors
Human RXRa, mouse RXR7 and chicken TRa were expressed
as fusions with glutathione-S-transferase (GST) using the
pGEX-2T, pGEX-3 and pGEX-1 bacterial expression vectors.
BL2 l(DE3)pLysS cells or DH5a cells containing these expression
vectors were induced for 1-2 hours with 0.4 mM IPTG after
the cells had grown to an O D ^ of - 0 . 6 . The GST fusion
proteins were affinity purified with glutathione-agarose columns
as described previously by Muscat and Downes et al., 1993 (7,
8). Quantification of TR and RXR after affinity purification was
achieved by Bradford determination with the Biorad protein assay
reagent, followed by SDS PAGE to determine the purity of the
preparation (these proteins were usually 20—50% pure).
Nuclear extracts and gel mobility shift assays
Nuclear extracts were prepared as decribed previously (7,8). Each
binding mixture (25-30 (d) contained 1-2 ng of a T4
Polynucleotide Kinase labeled DNA fragment, 1-30 pmol of
purified receptors or 5 - 1 0 /ig of crude nuclear extract, and 1 - 2
fig of poly dl-dC as a non-specific competitor [only when crude
nuclear extract was used] in Dignam buffer C. The assays were
incubated at room temperature for 20 min. and electrophoresed
through a 6% (20:1 polyacrylamide:bisacrylamide) gel in 80 mM
Tris borate and 2 mM EDTA. Gels were briefly soaked in 10%
acetic acid, dried and autoradiographed.
Western blots
Antigen containing cellular extracts (10 ng) were elecrophoresed
on 10% SDS PAGE, electroblotted/transferred onto Hybond
ECL. Non specific binding sites were blocked by immersing the
membranes in 5% dry milk, lxPBS and 0.02 % NaN3 for
l -2h . The membrane was subsequently washed in lxPBS
containing 0.1 % Tween 20, followed by an incubation with a
1 in 100 dilution of the antibody in blotto for 16h at 4°C with
shaking. Further steps involving secondary antibodies and the
catalyzed oxidation of luminol were carried out with the
Amersham ECL western blotting detection reagents according
to the manufacturer's protocols.
Proba myoD TRE a-MHC TRE
p M o l TR 1 2 4 - - - 1 2 4 1 2 1
p H o l RXR - - - 1 2 4 1 2 4 - - 1 2 1
Figure 1. The thyroid hormone and retinoid X receptors form heterodimeric
complexes on the myoD and a-MHC TREs. E.coti expressed and affinity purified
TRa and RXRa were incubated with the myoD and a-MHC TRE. H, D and
M denote heterodimer, dimer and monomer formation on the probe respectively.
Proba myoD ( - 3 3 7 / - 3 0 9 ) TRE
pmol TR a 2 4
pmol RXR Y
pmol RXR a
4 4 4 4
2 4
RESULTS
The retinoid X and thyroid hormone receptors form
heterodimers that bind with high affinity to the mouse myoD
TRE
We scanned the mouse myoD gene promoter (33) for a putative
thyroid hormone response element (TRE) that could account for
the in vitro and in vivo effects of 3,5,3' triiodo-L-thyronine (T3)
treatment on MyoD expression. Using the established DR-4
binding motif, AGGTCA [or a degenerate consensus motif;
RGG^-rYN; R= purine, Y = pyrimidine, N = nucleotide),
recognised by TR/RXR complexes, we identified a putative TRE
between nucleotide positions -337 and -309 (5' CTG-
AGGTCAGTACAGGCTGGAGGAGTAGA 3')- This putative
TRE sequence was arranged as a direct repeat of the core binding
motif with a 4 nucleotide gap and was accommodated by the
tandem direct repeat model [ 3 - 4 - 5 rule] proposed by Evans
and Rosenfeld (21,22,29,30). We characterized the putative
mouse myoD TRE between nucleotide positions -337/—309 by
demonstrating that it bound heterodimers of the thyroid hormone
and retinoid X receptor with high affinity.
Figure 2. The thyroid hormone receptor form heterodimeric complexes with either
the a or 7 isoform of die retinoid X receptor on the myoD TRE. E. coli expressed
and affinity purified TRa and RXRa/7 were incubated with the rayoD TRE.
H, D and M denote heterodimer, dimer and monomer formation on the probe
respectively.
A large body of evidence indicates that the RXR/TR
heterodimer rather than the TR homodimer is the entity diat
recognises functional thyroid hormone response elements (TRE)
(19,20,23,24,28,29,30). We investigated the ability of bacterially
expressed thyroid hormone and retinoid X receptors (TRa and
RXRa) to interact with the putative myoD TRE. We used the
well characterised rodent a-myosin heavy chain (MHC) TRE as
a heterodimerisation control; three groups have demonstrated that
RXR heterodimerizes with TR and markedly enhances the
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A \ * • * •
f\) myoD -337/ -309 gatcCTGAGGTCAGTACAGGCTGGAGGAGTAGA
rGH -190/-166 gatcAAGCTJUkGATCAGGGACGTGACCGC
rMBC -127/-1J9 qaccCTCTGG*CCTOCAGG»iaar»GCJlSCCCTGA
B)
PAL-0 gatcTCACCTCATGACCTGA
n>CKBPI-1016/-9B9 TTAGTiCCTCAAAAGCTCAGACACTGAA
HKT-1/E-box CCCCCCCAACACOGCTGCCTGAGCC
Probe: myoD-337/-3WTRE
Receptor: Thyroid Hormom/Rrlliukl X Receptor Heterodlir
Competitor: myoO rCH UHC PAL-0 RARE HEF-1
MoUr F.icen: C 10 60 10 60 10 10 10 60 10 «0 10 60 C
* • • • MMM • • WMI
Figure 3. A. The thyroid hormone response element (TRE) in the mouse myoD
promocer and from a number of other characterized genes. The synthetic direct
repeat response elements based on the 3 - 4 - 5 rule are also depicted. The
sequences of one strand of each double-stranded oligonucleotide probe are depicted.
The direction and location of the TREs are indicated by solid arrows. The dashed
arrow represents the location of a weak TRE m the MM promoter. These sequences
match the core sequence binding motif for the thyroid hormone receptor:
RGGT/ACN (R= purine, N=nucleotide) PAL-0 is a palindrotnic/inverted repeat
arrangement of motifs that confers a transcriptional response to RXR, TR and
RAR. CRBP I is a retinoic acid response element (RARE) in the cellular retinol
binding protein I. MEF-1/E-box, Myocyte enhancer factor 1; interact with basic
helix loop helix proteins. The nucleotide positions are indicated with respect to
the transcriptional start she at +1 . B. The myoD TRE interacts with TRa/RXRa
heterodimer in a sequence specific fashion. The effect of competition (10-60
fold molar excess), by self, GH, MHC and PAL-0 characterized TRE response
dements and other non-TRE DNA binding sites (MEF-1, mCRBP I RARE) on
the complex formed between the probe myoD (-337/ -309) TRE and the
TRa/RXRa heterodimer [4 pmol of each receptor]. The molar excess of each
DNA competitor is indicated. C, denotes the control binding reaction in the absence
of any unlabelled competitor.
binding to the MHC TRE. Electrophoretic mobility shift analyses
(EMSA) was used to evaluate the homodimeric and heterodimeric
binding of RXRa and TRa to the myoD TRE. Increasing
amounts (1,2 and 4 pmol) of RXRa and TRa were incubated
with fixed quantities of the myoD TRE and the defined MHC
TRE (Figure 1). This data demonstrated that TRa in pmol
qauntities did not interact with the myoD TRE, however, addition
of equivalent amounts of RXRa induced heterodimerization and
markedly enhanced binding of the receptor complexes to their
cognate sequences similar to the a-MHC TRE heterodimerization
control (Figure 1). The data here suggests that RXR may play
an important role in modulating the TR interaction to this
sequence. This data raises the possibility that the myoD TRE
-337/—309 may be a site for direct cross-talk between two
different hormonal signals (9-cis RA and T3) at the receptor
level.
The RXR family (a-, /3-, y-) is abundantly expressed in a
variety of adult tissues (34,35). RXRa and /3 are expressed in
many tissues but most abundantly in liver, lung, kidney and
cardiac/skeletal muscle. The RXR 7 gene encodes two isoforms
7I and y2 (35). The 7I isoform is specifically and abundantly
expressed in adult skeletal muscle (35). Hence, we examined the
ability of RXR7I relative to the RXRa isoform to induce
heterodimerization and markedely induce binding of TR to the
MyoD TRE. It was found that RXRa and RXR7I behaved in
a very similar fashion with respect to the formation of
heterodimers on the myoD TRE (Figure 2).
The interaction of the TR and RXR heterodimer with the
mouse myoD TRE [-337/-309] is specifically competed by
classical TREs
We conducted electrophoretic mobility shift analysis (EMSA)
competition studies using the classical and well characterized
natural rodent growth hormone (rGH) and a-myosin heavy chain
(aMHC) TREs, and the synthetic PAL-0 TRE sequences to assess
the sequence specific binding of the TRa/RXRa heterodimer to
the myoD [ — 337/ —309] sequences. The sequence of the
oligonucleotides used in this study are listed in figure 3A with
the TRE orientations defined by arrows. The competition studies
were carried out at 10 and 60 fold molar excess of oligonucleotide
with respect to the myoD TRE -337/-309 probe (Figure 3B).
These studies demonstrated that the complex formed between the
-337/-309 sequences and TRa/RXRa heterodimer could be
specifically competed by the established wild type TREs (that
have been demonstrated to interact with heterodimeric receptor
complexes). The rGH TRE only competed at > 100-fold excesses
(data not shown). However, the CRBP I RARE (cellular retinol
binding protein I, retinoic acid response element) and MEF-l/E-
box (Myocyte enhancer factor 1 binding sequences; that interact
with muscle specific helix loop helix -MyoD family of proteins)
did not compete for the formation of the heterodimeric complex
on the TRE. These results indicated that the -337/-3O9:
TRa/RXRa interaction was highly specific and involved in the
triiodo-thyronine signalling pathway.
Direct repeats of the sequence RGGTCA NXRGGTCA with
spacings of 4 and 5 specifically competed the formation of
the TRa/RXRa heterodimer on the MyoD TRE
A functional relationship among the RXR, Perixosome
proliferator activated receptor (PPAR), COUP-TF, vitamin D
receptor (VDR), TR and RAR has recently been described in
which these receptors bind and activate through direct repeats
of the AGGTCA motif separated by 1, 3, 4 and 5 (x=2, also
binds RXR and RAR). This rule applies to most of the natural
hormone response elements. In an effort to further characterize
the myoD TRE: TRa/RXRa complex we synthesized as
described in Kliewer et al. (32) an array of synthetic hormone
response elements as predicted by the 3 - 4 - 5 rule, arranged
as direct repeats of the AGGTCA motif with spacings of 1, 2,
3, 4 and 5 nucleotides [designated DR-1, DR-2, DR-3, DR-4
and DR-5 respectively] (Figure 4A).
We tested these hormone response elements in EMSA
competition assays to assess the specificity and gap/spacing
preference of the TRa: RXRa heteromeric binding to the myoD
-337/-3O9 sequence. DR-1, DR-2, DR-3, DR t^ and DR-5
were used in the binding reactions at 10 and 60-fold molar excess
with respect to the myoD TRE probe (Figure 4B). This data
indicated that DR^/DR-5 > DR-3 > DR-2 > DR-1
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A)
DR-2
BH-f
DR-4
Dfl-5
gatcAQGTCAgAGGTCA
gatcAGGTCAoflAGGTCA
SatcAGGTCAaggAGGTCA
gatcAGGTCAcaBOAGGTCA
aatcAOOTCAccaggAGGTCA
Probe:
Extract:
Competi tor:
( 100 % Motar Eitcsi)
myoD-337/-309TRE
Mvogenlc extract
B) Probe: myoOTRER*c*ptor Thyroid Hormom/TtaUnokf X Ftectptor Hct t rodlnw
Competitor myoD DR-1 Dfl-2 DR-3 DIM OH-3
Uolar Exoss: c 10 oo 10 oo 10 «o 10 JO 10 eo 10 eo c
Figure 4. A. The synthetic Direct Repeat response elements based on the 3—4-5
rule are depicted. The sequences of one strand of each double-stranded
oligonucleotide probe are depicted. The direction and location of the TREs are
indicated by solid arrows. DR-1, DR-2, DR-3, DR-4 and DR-5, are arranged
as direct repeats of the 'AGGTCA' motif with spacings of 1, 2, 3, 4 and 5
nucleotides. A functional relationship among the RXR, VDR, TR and RAR and
has recently been described in which these receptors bind and activate through
tandem direct repeats AGGTCA N, AGGTCA with spacing of 1,3,4 and 5
nucleotides respectively (x=2, mediates a positive response to RA and negative
response to T3). B. The MM TRE interacts with TRa/RXRa heterodimer and
was preferentially competed by direct repeats with a 4 or 5 nucleotide gap. The
effects of competition by a battery of hormone response elements, designated
DR-1, DR-2, DR-3, DR-4 and DR-5, on the complex formed between the myoD
TRE probe and TRa/RXRa [4 pmol of each receptor]. The molar excess of each
DNA competitor is indicated. C, denotes the control binding reaction in the absence
of any unlabelled competitor.
preferentially competed for the formation of the TRa/RXRa
heteromeric complex on the myoD TRE. These experiments
rigourously demonstrated that the TRa and RXRa heterodimer
complex on the myoD TRE was selectively competed by direct
repeats of the AGGTCA half site motif separated by 4 nucleotides
and provided strong evidence that the —337/-309 sequences
functioned as a TRE site according to the 3—4—5 rule. These
analyses were analogous to the work of Umesono et al. (22) that
showed DR-4/DR-5 > DR-3 preferentially competed for the
formation of the TRb heterodimeric complex on a sequence that
functioned as a TRE in transfection studies.
The myoD TRE interacts with a factor(s) from myogenic
nuclear extracts that is specifically competed by characterised
TREs and DR-4 sequence motifs
We conducted electrophoretic mobility shift analysis (EMSA)
competition studies using well characterized natural and synthetic
TRE sequences to assess the sequence specific binding of
myogenic nuclear factors to the myoD [—337/—309] sequence.
The sequence of the oligonucleotides used in this study are listed
in figure 3A with the TRE orientations defined by arrows.
Figure 5. The myoD TRE interacts with factors) from myogenic extracts in
a sequence specific fashion: The myoD TRE sequence interacts with factor(s)
in myogenic cextracts that are specifically competed by thyroid hormone response
elements. Myogenic extracts were derived from C2C12 cells that were
differentiated by 24h of mitogen withdrawal. The effect of competition by a number
of AGGTCA containing hormonal response elements on the complex formed
between the myoD TRE probe and myogenic factors. The molar excess of each
DNA competitor is indicated. C, denotes the control binding reaction in the absence
of any unlabelled competitor. MEF-1, myocyte enhancer factor-1.
Furthermore, we tested the battery of synthetic hormone response
elements (DR-1, DR-2, DR-3, DR^ and DR-5) in EMSA
competition assays to assess the specificity and gap/spacing
preference of the myogenic nuclear factor(s) from differentiated
C2C12 cells that interact with the myoD -337/-3O9 sequences.
These competitors were used in the binding reactions at ~
100-fold molar excess with respect to the myoD TRE probe
(Figure 5). These studies demonstrated that the complex formed
between the —337/ —309 sequence and the myogenic nuclear
factor(s) could be specifically competed by self, the
established/characterized a-MHC, PAL-0 and DR-4 TREs.
However, the CRBPI RARE, MEF-1/E-box (Myocyte enhancer
factor 1 binding sequences; that interact with muscle specific helix
loop helix -MyoD family of proteins); DR-1, DR-2, DR-3 and
DR-5 did not compete for the formation of the myogenic factor
on the myoD TRE. These results indicated that the sequence
specific interaction of the —337/—309 sequences with nuclear
factors was involved in the triiodo-thyronine signalling pathway.
Nuclear extracts were prepared from mouse myogenic C2C12
myoblasts and myotubes in different stages of differentiation to
assay the developmental regulation of TRE-bound proteins in
muscle. Specifically, extracts were isolated from proliferating
myoblasts (PMB), confluent myoblasts (CMB), and myotubes
(MT-1). These extracts were assayed for the levels of Oct-1,
which is a constitutively expressed factor and used to standardise
the amount of nuclear extracts used in the experiments. The
myoD TRE sequences interacted with a nuclear factor denoted
as MTBF \MyoD TRE Binding Factor(s)] in vitro that was
constitutively expressed during the differentiation of mouse
myogenic cell lines relative to the ubiquitously expressed Oct-1
protein (Figure 6A). Similarly, it has been observed that the
human skeletal a-actin and mouse myogenin TREs interact with
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myogenic nuclear factors that were constitutively expressed
during myogenesis (7,8). We further characterised the expression
of TRal [the hormone binding form] during myogenesis by
Western blot analyses using the the commercially available
antibody, PA1-211, from Affinity Bioreagents. The polyclonal
antibody, PA 1-211, specifically recognises TRal (48KDa) from
humans and rodents and not TRa2 or TR /3. It was derived from
a synthetic peptide (aa 403-410, extreme C-terminal end) that
is downstream from the point of sequence divergence from the
a-2 isoform. PA1-211 detected a ~ 50 KDa band in all stages
of muscle differentiation and in the COS-1 cells transfected with
pCMV-rTRa (Figure 6B). These experiments indicated that
TRa-1 protein was constitutively expressed during myogenesis.
The antisera also recognised a 130 kDa band in myogenic extracts
which was not present in the pCMV-rTRa transfected COS-1
cells, that indicated this band was due to non-specific binding.
These data correlate with the results of Carnac et al. (12) who
observed the constitutive expression of c-erb A a l and a2
mRNAs that encode TRal and TRa2 during the differentiation
of mouse myogenic cell lines.
Mutageoesis of the myoD TRE identifies the RGGTC A motifs
as essential TRa, RXRa binding sites
We characterized the nucleotides in the myoD TRE that interact
with TRa and RXRa heterodimer by mutating the myoD TRE
sequentially from the 5' to 3' direction by six mutations that
spanned the putative half site motifs. These mutant TREs were
designated, Ml—M5 (See Figure 7A) and used in EMSA
competition analyses to ascertain their ability to disrupt the
complexes formed between the myoD TRE and TRa/RXRa
heterodimer. We independently incubated wild type myoD TRE
[-337/-309] probe with cTRa/RXRa heterodimer (Figure 7B)
and competed with 10, and 60 fold molar excesses of the Ml,
M2, M3, M4 and M5 mutant TREs. Figure 7B depicts the ability
of the mutant myoD TRE oligos, Ml—M5, to compete for
binding to the heterodimer. The mutant myoD TREs Ml, M3,
and M5 competed efficiently for binding to the TRa/RXRa
heterodimer. This demonstrated that the sequences flanking the
two half-site RGGTCA motifs and the sequence of the 4nt gap
were not important for binding to the complex. In contrast, the
M2 and M4 mutant myoD TREs did not compete for binding
to the heterodimeric complex. This data strongly implicated the
importance of the half site sequence and requirement for the direct
repeats [i.e. two half sites] in the efficient formation of a TR/RXR
heterodimer on the myoD TRE.
Sequences between nudeotide position —337 and —309 in the
mouse myoD promoter confer T3 regulation to an
enhancerless simian virus 40 promoter
The formation of TR/RXR heterodimers that strongly and
selectively interact with a target sequence, correlate with a
functional T3 dependent trans-activation in vivo. An important
question to address is whether the strong and specific
heterodimeric binding between TR and RXR on the myoD TRE
can be directly correlated with T3 dependent trans-activation in
vivo. We then cloned the —337/ —309 sequences into an
enhancerless SV40 promoter linked to the firefly luciferase gene,
[pGL-2-promoter, Promega] and conducted experiments to see
if the myoD TRE conferred appropriate hormonal regulation to
a heterologous promoter. The resultant plasmid, pmyoD-GL-p,
contained three copies of the myoD tRE; similar multiple copy
plasmids have been utilized by Chambon, Evans, Phafl and their
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Figure 6. A. The myoD TRE sequence interacts with constitutively expressed
fector(s) in myogenic extracts. PMB and CMB denote extracts derived from
proliferating and confluent C2C12 myoblasts. MT-1 denote extracts derived from
myotubes, 1 day after mitogen withdrawal. Oct-1, is a factor that is constitutively
expressed and unaffected by the mitotic state of the cell. MTBF, denotes MyoD
TRE Binding Factors). F, denotes free probe. N.S, denotes non-specific bands
as a results of single stranded DNA binding proteins. B. The thyroid hormone
receptor al is constitutively expressed during the differentiation of mouse
myoblasts. Whole cell extracts were derived from mouse C2C12 cells. PMB and
CMB denote extracts derived from proliferating and confluent myoblasts. MT-1
and MT-4 denote extracts derived from differentiated myotubes, 1 and 4 days
after mitogen withdrawal by 24h of mitogen withdrawal. Lane 1, PMB; Lane
2, CMB; Lane 3, MT-1; Lane 4, MT^t and Lane 5, COS-1 cells transfected
with pCMV-TRa. Western blot analyses was performed with the Affinity
Bioreagents antibody PA 1-211 that specifically recognises TRal from humans
and rodents.
colleagues in these types of experiments. (19,24,36,37,38). This
plasmid, pmyoD-GL-p was transfected into COS-1 cells and
grown in thyroid hormone and retinoid deficient medium in the
presence of co-transfected TRa (2 /tg). The myoD TRE
sequences conferred a ~ 4 to 5 fold induction after T3 treatment
to the enhancerless SV40 promoter (Figure 8A, lanes 5 and 6),
whereas the basal vector, pGL-2-p was not stimulated by T3
(figure 8A, lanes 1 and 2). The basal vector, pGL-2-p, did not
show any significant induction in the presence of RXRa (2 /tg)
alone and 9-cis RA (Figure 8A, lanes 3 and 4), however, the
level of expression from pmyoD-GL-p was significantly
repressed, relative to the basal vector (Figure 8A, lanes 7 and
8). Furthermore, RXRa (2 /tg) completely suppressed the T3
dependent trans-activation (Figure 8A, lanes 9 and 10). We
investigated this effect in more detail by co-transfecting the
reporter, pmyoD-GL-p, in the presence of increasing quantities
of RXRa (10-300 ng) with a fixed quantity of TRa (2 /tg). This
experiment indicated that > 10 ng of co-transfected RXRa
expression vector repressed the T3 dependent trans-activation
(Figure 8B, lanes 1-5). These observations are supported by
the recent report from the Phafl group (39) that demonstrated
RXRs in excess in the presence of 9-cis RA form homodimers
that sequester RXR from RXR-TR heterodimers and lead to the
repression of the T3 response by ligand (9-cis RA) induced
squelching. These results confirmed that the cis-acting region
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A) WTU3 TYPE(-337/309)
A)
H3
HS
GACTCCAGTCATGTCCGACCTCCTCATCT
AAAAGGTCAGTACAGGCTGGAGGAGTAGA
1J i1CCAGTCATGTCCGACCTCCTCATCT
CTG nTJUITGTACAGGCTGGAGGAGTAGA
GACXJUITJICATGTCCGACCTCCTCATCT
CTGAGGTCACAGGAGGCTGGAGGAGTAGA
GACTCCAGTCTOCTCCGACCTCCTCATCT
CTGAGGTCAGTACITTAAAGAGGAGTAGA
GACTCCAGTCATGJUUTTTCTCCTCATCT
CTGAGGTCAGTACAGGCTGGrTTAAAAGA
GACTCCAGTCATGTCCGACCJUlATrTTCT
B) Probe: mjoD TRER«*p«or: Thvroid Hormone/Rrtlnold X Rfctptor Hettrodlmrr
Competitor: M l M2 M3 M4 M5
Molar Eirtfs: C 10 60 10 60 10 60 10 60 10 60 C
Ptssrrdd
1 pGL-2-p
2. pQL-2-p
3. pGL-2-p
4 pQL-2-p
5 pMyoD-GL-p
6 pUyoD-GL-p
7 pMyoO-GL-p
8. pMyoO-GL-p
9 pMyoO-QL-p
10. pMyoO-GL-p
TR RXR T3 RA
B)
Ptwnld RXR
1 pMyoO-GL-p
2 pMyoD-GL-p 10ng
3 pMyoO-GL-p 30ng
4 pMyoO-GL-p 100ng
5. pMyoO-QL-p 300ng
RA T)
Figure 7. A. Pictorial representation of the various site specific mutation in the
mouse myoD TRE. The wild type TRE sequence is depicted and the mutations
in the Ml, M2, M3, M4 and M5 TREs are denoted by bold italic text. B.
Mutational analyses of the mouse myoD TRE. The core receptor binding motifs
in the myoD TRE are important for binding. The effects of competition by a
battery of mutations in the myoD TRE, designated Ml, M2, M3, M4 and M5
on the complex formed between the myoD TRE probe and TRa/RXRa
heterodimer. The molar excess of each DNA competitor is indicated. C, denotes
the control binding reaction in the absence of any unlabelled competitor.
between nucleotide positions —337/-309 functions as a
positively acting TRE in the muscle specific mouse myoD
promoter.
DISCUSSION
Thyroid hormones are major determinants of skeletal muscle
differentiation and play a role in regulating contractile protein
isoform expression during muscle maturation. Triiodo-L-
thyronine treatment of the myogenic cell line, C2.7, increased
the steady state level of myoD mRNA and resulted in increased
MyoD gene transcription in myoblasts. Furthermore, myogenin,
myosin light chain 1A and troponin T, were precociously
induced, and indicated that T3 promotes terminal differentiation
(12). Recently, it has been demonstrated that MyoD selectively
accumulates in fast twitch fiber types, however, plantaris muscle,
predominantly fast twitch, accumulates considerable myogenin
mRNA. There transgene data suggested that MyoD activity was
restricted to a subset of non HA fast fibres (i.e IIx and/or lib)
(11). Furthermore, Peterson and colleagues showed that thyroid
hormone treatment results in the significant induction of MyoD
and fast DA myosin heavy chain mRNA in slow twitch soleus
Figure 8. The myoD TRE confers hormonal regulation to an enhancerless SV4O
promoter. The mean RLU's, relative light units, are shown for the plasmid,
pMyod-GL-p, containing the myoD TRE sequence cloned into the pGL-2-promoter
vector (See Materials and Methods for specific cloning details). Results are shown
for transient transfections in COS-1 cells. Mean values and standard deviations
were derived from a triplicate experiment. A. The myoD TRE sequence confers
a T3 response to the SV40 promoter in the plasmid pMyoD-GL-p. T3, denotes
triiodo-L-thyronine and RA, denotes 9-cis RA. B. Over-expression of RXR
represses the trans-activation of pMyoD-GL-p by TR/T3. T3, denotes triiodo-
L-thyronine and RA, denotes 9-cis RA.
fibers and a slight activation of fast IIB MHC mRNA (11). Soleus
muscle from euthyroid animals contains fast DA MHC , but not
MyoD or II B fast MHC (1,11).
Our study, has shown that the T3 influenced induction of myoD
mRNA in rodent muscle and myogenic cell lines involves direct
transcriptional mechanisms. Transfection experiments and EMSA
were used to identify a functional T3 response element (TRE)
in the mouse myoD gene. This TRE is located between nucleotide
positions -337 and -309 (5' CTGAGGTCAGTACAGGCT-
GGAGGAGTAGA 3') and is accommodated by the DR-4 TR/
RXR binding motif, RGGTCA. This TRE sequence conferred
a ~ 4 - 5 -fold induction to an enhancerless SV40 promoter, after
T3 treatment in a TR-dependent manner. EMSA experiments
showed that Escherichia coli expressed/affinity purified TRa and
RXRa/7 formed a heterodimeric complex that bound very
efficiently to the myoD TRE. This is in agreement with all the
recent data that defines the heterodimer rather than the
homodimer as the entity that efficiently recognises thyroid
hormone response elements. Futhermore, the TR/RXR complex
on the myoD TRE was specifically and selectively competed by
other natural and synthetic TREs; in contrast a natural RARE
 at UQ Library on October 18, 2012
http://nar.oxfordjournals.org/
D
ow
nloaded from
 
590 Nucleic Acids Research, 1994, Vol. 22, No. 4
and the DR-1, DR-2 and DR-3 sequences that interacted with
a wide variety of other steroid receptors (41) [RXR/PPAR,
COUP-TF and VDR]; and the MEF-1/E-box sites did not
compete for the formation of the TR/RXR complex on the myoD
TRE. These in vitro binding data correlated with the ability of
these receptors after hormone treatment to trans-activate the
myoD TRE in vivo, in agreement with a variety of other studies.
Mutagenesis of the myoD TRE indicated that the two core
RGGTCA binding motifs were necessary for efficient
TRa/RXRa heterodimer formation. The myoD TRE interacted
with MTBF from myogenic nuclear extracts that was specifically
competed by the characterized the a-MHC, PAL-0 and DR-4
TREs but not by other cis-acting sequences. Our experimeats
have demonstrated that the —337/-309 cis-acting sequence
interacts with the heterodimeric TR/RXR receptor complex with
high affinity and sequence specificity similar to the well
characterised a-MHC TRE, and that this sequence conferred an
appropriate T3 response. This data satisfies the criteria that have
evolved to define thyroid hormone response elements.
Our experiments suggest that the RXRs may modulate the
interaction of TRa to the myoD TRE and that the -337/ -309
sequence in the mouse myoD gene is a target for direct cross-
talk between two different hormonal signals (T3 and 9-cis RA)
at the receptor level. This correlates with the abundant levels
of c-erbAa (TRa) and RXR a/y in adult muscle and myogenic
cultures. To our knowledge this is the first demonstration of
heteromeric binding of TRa and RXRa/7 to a TRE in the myoD
gene, expressed specifically in skeletal muscle. Our results
provide a molecular explanation for the increased myoD gene
transcription observed after T3 treatment of C2C12 myogenic
cultures and the activation of myoD expression in slow twitch
muscle fibres.
How does T3 activate myoD expression in slow fibres and
induce fast contractile protein gene transcription?
The effects of thyroid hormone levels in adult animals are only
apparent in long term intoxication (9,10). T3 treatment results
in an increase in myoD mRNA in soleus muscle and type II fast
fibers, whereas hypothyroidism reduces the number of these
fibres (9,10). In hypothyroid rats expression of adult fast myosin
is drastically reduced and neonatal myosin is abnormally high.
The multigene MHC family is repressed and activated by thyroid
hormone in a tissue and fiber type specific manner (1). These
findings suggest that the hormonal influences on HLH expression
and fiber type are quite complex and involve a variety of
differentially regulated factors. We suggest that the differential
expression and steady state levels of TR accessory factor
isoforms, e.g RXR a, /3 and 7 genes, in different muscle twitch
types may mediate fiber type specific activation events. Although,
differences in the uptake or processing of T3/T4 in different
skeletal muscle types may account for some of these differences
(42). All TREs interact efficiently with TR/RXR heterodimers
in vitro, however, specific TREs display distinct RXR isoform
preferences with respect to functional fra/u-activation (see 37).
Furthermore, some TRE heterodimer complexes are very
sensitive to RXR levels (7, 39). In support of our suggestion,
it was recently shown that the RXR isoforms a, /3 and 7 are
expressed at different levels in skeletal muscle (34,35) and
differentially modulated by T3 (43) (RXR /3 and 7 steady state
mRNA levels are increased and repressed respectively). Our
present study supports the hypothesis that T3 directly targets the
hierarchical HLH regulators. Our recent identification and
characterization of the TRE in the skeletal a-actin gene (7) that
mediates hormonal induction implies that T3 simultaneously
targets the hierarchical HLH regulators and the contractile protein
genes during the regulation of terminal differentiation. Fine tuned
expression is most probably achieved by the MyoD family and
other intermediate regulators such as MEF-2/RSRF family
(44,45,46) that are part of a positive autoregulatory loop that
maintain the required threshold levels of these muscle specific
transcription factors. We are currently examining the fiber type
specific distribution of the RXR isoforms and the relative levels
of other c-erb A a gene products TRa2 and rev-erb A a which
are known to modulate the function of TR.
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